Cross-Sector entity
Of the tracked stories, 3 of 3 also mention Johnson & Johnson, the most common co-covered peer. The clearest coverage concentration is market-trends: 1 of 3 stories, with the rest divided among 2 other categories. JNJ-2113 appears in 3 tracked Cross-Sector stories from February 25, 2026.
3 verified stories tracked
Last mentioned: Feb 25, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 3 also mention Johnson & Johnson, the most common co-covered peer. The clearest coverage concentration is market-trends: 1 of 3 stories, with the rest divided among 2 other categories. JNJ-2113 appears in 3 tracked Cross-Sector stories from February 25, 2026. The tracked stories average 2 original sources each.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering JNJ-2113. Shared-story counts are live from our verified record — not editorial picks.
Institutional Exit Revealed
13F filings reveal a $170 million divestment by a major institutional fund.
120% Gain Milestone
PTGX stock reaches a 120% gain milestone from its 52-week low.
J&J Partnership Milestone
Johnson & Johnson advances JNJ-2113 into late-stage trials, validating oral peptide tech.
120% Rally
Stock price reaches a 12-month peak following sustained clinical momentum.
Phase 3 Data Release
Positive Phase 3 data for rusfertide in polycythemia vera triggers initial stock rally.
J&J Partnership Expansion
Johnson & Johnson expands the scope of the oral peptide collaboration.
Phase 2 Success
JNJ-2113 reports positive Phase 2 data in plaque psoriasis, triggering milestone payments.
Protagonist Therapeutics has seen its stock price more than double following clinical breakthroughs in its oral peptide portfolio, yet a major institutional investor has liquidated a $170 million position. This tactical exit highlights the tension between clinical optimism and institutional profit-taking as the company nears critical Phase 3 milestones.
Protagonist Therapeutics shares have soared 120% following clinical and regulatory milestones, but a recent $170 million institutional exit is raising questions about the stock's near-term ceiling. The move highlights a growing divergence between retail momentum and institutional profit-taking in the biotech sector.
Protagonist Therapeutics has seen its share price skyrocket by 120% following significant clinical and regulatory milestones, yet a major institutional investor has disclosed a $170 million exit. This divergence highlights a classic 'sell the news' moment or strategic rebalancing amidst a period of high valuation for the peptide-based drug developer.
Source: fool.com · finance.yahoo.com
